Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Advancing Biomedical Research in HK

Image Credits: CUHK, Press Release

A Memorandum of Understanding (MoU) was signed by the Chinese University of Hong Kong (CUHK) and a biotechnology company based in China with the aim of strengthening their collaboration in innovative biomedical research, fostering talent development and promoting the commercialisation of research findings.

During the MoU signing ceremony, witnessed by high-profile attendees such as legislative council members and executives, CUHK’s Pro-Vice-Chancellor (Strategic Development) and the biotechnology firm’s Executive President signed the agreement. CUHK’s Provost Professor and the company’s Chairman were also present. Additionally, CUHK’s Office for Greater Bay Area Developments Director and the company’s Vice President were in attendance.

By signing the MoU, the two parties have embarked on a significant partnership in biomedical science initiatives that will extend throughout the Guangdong – Hong Kong – Macao Greater Bay Area. This collaboration demonstrates the commitment of both institutions to bolstering Hong Kong’s position as a global hub for innovation and technology. It is a concrete step towards realising a new vision for technological development and supporting Hong Kong’s contribution to national progress.

CUHK’s Provost shared that CUHK, established in 1963 as a teaching-oriented institution, transformed into a research-oriented university in the 1980s and 90s. Over time, the university has further evolved to emphasise research, education, and innovation.

He expressed that the development of innovative technology, particularly in biomedicine, cannot be achieved through the efforts of a single university alone. He is confident that the MoU signed is the start of closer collaboration with both local and international enterprises in the future.

The s Chairman of the biotechnology company expressed his delight in signing the agreement with CUHK and highlighted the university’s strong research and development background. He also noted that biotechnology has a leading role in regional and international projects. He believes that the collaboration between the two entities will combine their resources and expertise to accelerate the commercialisation of research findings, facilitate the clinical development of new therapies and contribute to the advancement of biomedicine and healthcare.

Legislative Council Member, the Hon Duncan Chiu, expressed the government and the Legislative Council’s longstanding focus on fostering collaboration between institutions and enterprises in research and development. He expressed his satisfaction in witnessing CUHK’s commitment to collaborating with more enterprises to contribute to Hong Kong’s growth as a global innovation and technology hub.

The MoU represents a significant milestone in the parties’ collaboration towards advancing biomedical research, talent cultivation, and commercialisation of research outcomes in the Greater Bay Area and beyond. This partnership marks a commitment towards leveraging their respective resources and expertise to accelerate the development of new therapies, improve healthcare outcomes, and support Hong Kong’s role in contributing to national development.

The collaboration also reinforces Hong Kong’s position as a global hub for innovation and technology and highlights the importance of cooperation between institutions and enterprises in research and development. Overall, this agreement signifies a promising future for innovative biomedical research in the region.

The global biotechnology market has seen remarkable growth in recent years, with an estimated value of US$ 1,023.92 billion in 2021. The market is expected to continue to expand at a compound annual growth rate (CAGR) of 13.9% from 2022 to 2030, driven by a variety of factors such as government support, standardisation of clinical studies, and the growing focus on personalised medicine.

The increasing number of orphan drug formulations and emerging innovative biotechnology companies are also fuelling the market’s growth. With such developments and a growing focus on research and development, the biotechnology market is expected to see continued expansion in the coming years, creating new opportunities for both established companies and newcomers to the field.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and consulting services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,800 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently, and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity, and service. For more information, visit